Billing News Jun 2022



Congressional Champions Introduce the Saving Access to Laboratory Services Act (SALSA)

  • June 22, 2022

On June 22, 2022, new legislation was introduced that is intended to permanently reform PAMA and set the Medicare CLFS back on a sustainable path. The legislation titled the Saving Access to Laboratory Services Act (SALSA), has been introduced in both the Senate and House by Sens. Sherrod Brown (D-OH) and Richard Burr (R-NC), along with Reps. Bill...

Read



CMS Rescinds Proposal to Delete NOC ICD-10 Codes

  • June 20, 2022

CMS is rescinding its proposal to delete the NOC (Not Otherwise Specified) ICD-10-CM codes from NCD 90.2 for NGS testing on advanced cancer patients. In May 2021, CMS announced it would be deleting a number of ICD-10 cancer diagnosis codes which made breast and lung cancer claims payable under NGS testing effective July 1, 2022. However,...

Read



Cigna Reverses Deposits in Error

  • June 15, 2022

As a result of a system glitch that occurred between May 19 and May 23, Cigna has incorrectly issued deposit reversals impacting numerous providers between 5/31/2022 and 6/1/2022. Cigna has informed XIFIN that they are aware of the system error and are working internally to address and correct the glitch. Payments should be reissued once the...

Read



Laboratory Claims Submitting with a CLIA Number

  • June 13, 2022

Starting June 24, 2022, claims submitted with more than one CLIA number will be denied as un-processable. CMS Internet Only Manual (IOM), Publication 100-04, Medicare Claims Processing Manual, Chapter 16, Section 70.10  Laboratory claims submitted without the required CLIA number are returned as un-processable. If the CLIA number is...

Read



Guidelines Update Supports Use of Genomic Tests in Early Prostate Cancer Management

  • June 13, 2022

A new update to guidelines from the American Urological Association for the management of patients with localized early-stage prostate cancer has endorsed selective use of genomic biomarker tests. The AUA's 2022 update now states that clinicians may use tissue-based genomic biomarkers when added risk-stratification could alter their clinical...

Read



Early Alzheimer's Test Gets FDA Nod

  • June 13, 2022

The first in vitro diagnostic tool to help detect early Alzheimer's disease was authorized by the FDA on Wednesday. The assay measures the ratio of beta-amyloid 1-42 to beta-amyloid 1-40 in cerebrospinal fluid (CSF). The Lumipulse G ß-Amyloid Ratio (1-42/1-40) test is intended to be used in adults 55 and older presenting with cognitive impairment...

Read



CDC Plans to Stop Reporting Suspected Covid Cases to Ease Burden

  • June 13, 2022

The Centers for Disease Control and Prevention plans to simplify the Covid-19 hospital data it collects as the demands of the pandemic evolve and some assembled information has become outdated or redundant. The agency is likely to stop collecting data from hospitals on suspected Covid cases that haven’t been confirmed by tests, for example, and...

Read



Senate Seeks to Reform Diagnostic Oversight via User-Fee Bill, Sparking Mixed Response

  • June 13, 2022

U.S. lawmakers again are trying to pass legislation to create a new regulatory framework for in vitro and laboratory-developed tests, this time by modifying the FDA user-fee bill that is now working its way through Congress. The revised bill from the Senate Committee on Health, Education, Labor and Pensions (HELP) features a modified version of...

Read